170 related articles for article (PubMed ID: 22825226)
1. Determining predictors of response to exenatide in type 2 diabetes.
Anderson SL; Trujillo JM; McDermott M; Saseen JJ
J Am Pharm Assoc (2003); 2012; 52(4):466-71. PubMed ID: 22825226
[TBL] [Abstract][Full Text] [Related]
2. Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.
Singhal M; Unni S; Schauerhamer M; Nguyen H; Hurd J; McAdam-Marx C
J Manag Care Spec Pharm; 2017 Mar; 23(3):267-275. PubMed ID: 28230449
[TBL] [Abstract][Full Text] [Related]
3. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Blonde L; Klein EJ; Han J; Zhang B; Mac SM; Poon TH; Taylor KL; Trautmann ME; Kim DD; Kendall DM
Diabetes Obes Metab; 2006 Jul; 8(4):436-47. PubMed ID: 16776751
[TBL] [Abstract][Full Text] [Related]
4. Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting.
Pawaskar M; Li Q; Hoogwerf BJ; Reynolds MW; Faries D; Engelman W; Bruhn D; Bergenstal RM
Diabetes Obes Metab; 2012 Jul; 14(7):626-33. PubMed ID: 22321776
[TBL] [Abstract][Full Text] [Related]
5. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
[TBL] [Abstract][Full Text] [Related]
6. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
Zinman B; Hoogwerf BJ; Durán García S; Milton DR; Giaconia JM; Kim DD; Trautmann ME; Brodows RG
Ann Intern Med; 2007 Apr; 146(7):477-85. PubMed ID: 17404349
[TBL] [Abstract][Full Text] [Related]
7. Real-world clinical outcomes and predictors of glycaemic and weight response to exenatide once weekly in patients with type 2 diabetes: The CIBELES project.
Gorgojo-Martínez JJ; Gargallo-Fernández MA; Brito-Sanfiel M; Lisbona-Catalán A
Int J Clin Pract; 2018 Mar; 72(3):e13055. PubMed ID: 29341370
[TBL] [Abstract][Full Text] [Related]
8. The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review.
Best JH; Lavillotti K; DeYoung MB; Garrison LP
Diabetes Obes Metab; 2012 May; 14(5):387-98. PubMed ID: 22074017
[TBL] [Abstract][Full Text] [Related]
9. Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes.
Rosenstock J; Shenouda SK; Bergenstal RM; Buse JB; Glass LC; Heilmann CR; Kwan AY; MacConell LA; Hoogwerf BJ
Diabetes Care; 2012 May; 35(5):955-8. PubMed ID: 22432107
[TBL] [Abstract][Full Text] [Related]
10. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
Blevins T; Pullman J; Malloy J; Yan P; Taylor K; Schulteis C; Trautmann M; Porter L
J Clin Endocrinol Metab; 2011 May; 96(5):1301-10. PubMed ID: 21307137
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.
Levin PA; Mersey JH; Zhou S; Bromberger LA
Endocr Pract; 2012; 18(1):17-25. PubMed ID: 21742605
[TBL] [Abstract][Full Text] [Related]
12. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.
Yoon NM; Cavaghan MK; Brunelle RL; Roach P
Clin Ther; 2009 Jul; 31(7):1511-23. PubMed ID: 19695400
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States.
Pawaskar M; Li Q; Hoogwerf BJ; Reynolds MW; Lee LJ; Fonseca V
Endocr Pract; 2012; 18(5):700-11. PubMed ID: 22982784
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice.
Hwang YC; Kim A; Jo E; Yang Y; Cho JH; Lee BW
BMC Endocr Disord; 2017 Oct; 17(1):68. PubMed ID: 29065865
[TBL] [Abstract][Full Text] [Related]
15. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis.
Glass LC; Qu Y; Lenox S; Kim D; Gates JR; Brodows R; Trautmann M; Bergenstal RM
Curr Med Res Opin; 2008 Mar; 24(3):639-44. PubMed ID: 18218179
[TBL] [Abstract][Full Text] [Related]
16. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
King AB; Montanya E; Pratley RE; Blonde L; Svendsen CB; Donsmark M; Sesti G
Endocr Pract; 2013; 19(1):64-72. PubMed ID: 23186975
[TBL] [Abstract][Full Text] [Related]
17. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
[TBL] [Abstract][Full Text] [Related]
18. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
Klonoff DC; Buse JB; Nielsen LL; Guan X; Bowlus CL; Holcombe JH; Wintle ME; Maggs DG
Curr Med Res Opin; 2008 Jan; 24(1):275-86. PubMed ID: 18053320
[TBL] [Abstract][Full Text] [Related]
19. Effects of exenatide in poorly controlled type 2 diabetes.
Kaimal N; Schofield J; Zaki A; Patel R; Sharma M; McCourt E; Imtiaz KE
QJM; 2012 Apr; 105(4):321-6. PubMed ID: 22056400
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors associated with glycaemic response to exenatide in Chinese patients with type 2 diabetes mellitus.
Wang T; Zhang F; Wang X; Li X; Ling H; Lv D; Yin X; Lu Q
J Clin Pharm Ther; 2020 Oct; 45(5):1050-1057. PubMed ID: 32176827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
